Ahmed, SanaMcCollin, Sandra P.Martí-Carvajal, ArturoAkus, MonicaBaron, David W.Abdul Razzaq, SaraScudder, PaigeHonigsberg, Elizabeth J.Nasir, SaifuddinPeng, KangningJahanfar, Shayesteh2026-09-282026-09-282026-08-10Ahmed, S, McCollin, S P, Martí-Carvajal, A, Akus, M, Baron, D W, Abdul Razzaq, S, Scudder, P, Honigsberg, E J, Nasir, S, Peng, K & Jahanfar, S 2026, 'Glucagon-like peptide-1 receptor agonist-based regimens compared with metformin-based regimens for preventing cardiovascular disease in adults with type 2 diabetes mellitus', The Cochrane database of systematic reviews, vol. 8, pp. CD016380. https://doi.org/10.1002/14651858.CD0163801465-1858PubMedCentral: PMC13455057https://hdl.handle.net/10641/8289Publisher Copyright: Copyright © 2026 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.Objetivos: Este es un protocolo para una revisión de Cochrane (intervención). Los objetivos son los siguientes: Evaluar los beneficios clínicos y los efectos adversos de los regímenes basados en agonistas del receptor del péptido 1 similar al glucagón, comparados con los regímenes hipoglucemiantes basados en metformina, para prevenir eventos cardiovasculares que incluyen mortalidad por todas las causas, mortalidad cardiovascular, infarto de miocardio no fatal, accidente cerebrovascular no fatal y eventos adversos metabólicos (incluida la hipoglucemia transitoria) en adultos con diabetes mellitus tipo 2 en ámbitos de prevención primaria y secundaria. [Traducción automática al español; idioma original: inglés.]OBJECTIVES: This is a protocol for a Cochrane review (intervention). The objectives are as follows: To assess the clinical benefits and adverse effects of glucagon-like peptide-1 receptor agonist-based regimens, compared with metformin-based glucose-lowering regimens, for preventing cardiovascular events including all-cause mortality, cardiovascular mortality, non-fatal myocardial infarction, non-fatal stroke, and metabolic adverse events (including transient hypoglycemia) in adults with type 2 diabetes mellitus across primary and secondary prevention settings.294505enghttp://creativecommons.org/licenses/by-nc-nd/4.0/Pharmacology (medical)SDG 3 - Good Health and Well-beingYesjournal articleopen access10.1002/14651858.CD016380https://www.scopus.com/pages/publications/105046783748https://www.scopus.com/pages/publications/105046783748#tab=citedBy